DiaMedica Therapeutics Inc DMAC

Healthcare Biotechnology

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.

NDAQ:DMAC - Post by User

DiaMedica Therapeutics Inc

<< Previous

Bullboard Posts

Post by EdgeTrade404on Nov 25, 2024 10:52am

19 Views

Post# 36329051

Momentum Watch: $DMAC and $MYNZ

$DMAC surged after the Wainright H.C. upgrade, breaking resistance at $4.50 with strong volume. RSI confirms bullish momentum, and $5.00 looks like the next target. Meanwhile, $MYNZ is holding its base near 0.22, waiting for volume to confirm the next move higher.

<< Previous

Bullboard Posts

Sirios Resource discovers visible gold in Quebec